Novartis AG (LSE:0HKE)
£ 3657.04 0 (0%) Market Cap: 60.95 Bil Enterprise Value: 74.78 Bil PE Ratio: 14.34 PB Ratio: 5.34 GF Score: 77/100

Novartis AG to Discuss Beovu® FDA Approval Investor Call Transcript

Oct 08, 2019 / 12:30PM GMT
Operator

Good morning and good afternoon, and welcome to the Beovu FDA Approval Investor Call. (Operator Instructions) and the conference is being recorded. (Operator Instructions) A recording of the conference call, including the Q&A session, are available on our website shortly after the call ends. (Operator Instructions)

With that, I would like to hand it over to Samir Shah, Global Head, Investor Relations. Please go ahead, sir.

Samir Shah
Novartis AG - Global Head of IR

Thank you very much. And good morning and good afternoon, everybody. It's a pleasure to talk to you today about our Beovu FDA approval. And I'd like to thank you all for taking the time to listen to this investor call.

Before we start, I'll just read the safe harbor statement. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties and other factors. These may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statement. Please refer to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot